European Journal of Pediatrics

, Volume 154, Issue 7, pp 593–594 | Cite as

Neurological deterioration in patients with urea cycle disorders under valproate therapy—a cause for concern

  • Adrian C. Sewell
  • Hans-Josef Böhles
  • Jürgen Herwig
  • Mübeccel Demirkol
Letter to the Editors
  • 22 Downloads

Keywords

Public Health Urea Valproate Neurological Deterioration Urea Cycle 

References

  1. 1.
    Christmann D, Hirsch E, Mutschler V, Collard M, Marescaux C, Colombo J-P (1990) Late diagnosis of congenital argininemia during administration of sodium valproate. Rev Neurol Paris 146: 764–766PubMedGoogle Scholar
  2. 2.
    Coulter DL, Allen RJ (1981) Hyperammonemia with valproic acid therapy. J Pediatr 99: 317–319PubMedGoogle Scholar
  3. 3.
    Honeycutt D, Callahan K, Rutledge L, Evans B (1992) Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 42: 666–668PubMedGoogle Scholar
  4. 4.
    Patel JS, Van T'Hoff W, Leonard JV (1994) Arginase deficiency presenting with convulsions. J Inherited Metab Dis 17: 254PubMedGoogle Scholar
  5. 5.
    Tokatli A, Coskun T, Cataltepe S, Özalp I (1991) Valproate-induced lethal hyperammonaemic coma in a carrier of ornithine carbamoyltransferase deficiency. J Inherited Metab Dis 14:836–837PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Adrian C. Sewell
    • 1
  • Hans-Josef Böhles
    • 1
  • Jürgen Herwig
    • 1
  • Mübeccel Demirkol
    • 2
  1. 1.Department of PaediatricsUniversity Children's HospitalFrankfurtGermany
  2. 2.Department of Nutrition and MetabolismChildren's HospitalÇapa-IstanbulTurkey

Personalised recommendations